论文部分内容阅读
BACKGROUND: CD40L gene therapy offers an attractive option for lung cancer because of its multiple antitumor activities.However, membrane-bound CD40L may be proteolytically cleaved to form soluble CD40L (sCD40L), which leads to adverse effects.